Have any questions? 706-721-6582 or cts@augusta.edu
- TRX518-004: A Dose Escalation and Expansion Study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Clinical Trial
TRX518-004: A Dose Escalation and Expansion Study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Patients are being asked to take part in a research study sponsored by Leap Therapeutics that tests an investigational drug called TRX518, this is the study drug, combined with one approved US drug Cyclophosphamide or combined with two approved US drugs: Cyclophosphamide and Avelumab. The combination of the drugs is also investigational. Investigational means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). Patients are being asked to take part in this research study because they have an advanced solid tumor cancer and because standard drugs to treat their disease are no longer effective, or no effective treatment is known for their disease.
Eligibility Criteria
- Male or female, aged 18 years or older Metastactic or locally advanced, incurable solid tumor one prior line of systemic therapy for metastatic or locally advanced disease Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.